Regulatory Novartis receives European Commission approval for Itvisma for spinal muscular atrophy PharmaTimesEC backs first gene replacement therapy for broad sma populationRare DiseaseRead full story pharminent July 2, 2026 (Last updated: July 3, 2026) PharmaTimes EC backs first gene replacement therapy for broad sma population Rare Disease Read full story Post navigation Previous: AZ forges ever-closer ties with China’s CSPC PharmaNext: Biogen Bets on Tau at AAIC: Diranersen Phase 2 CELIA Data Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026